StreetInsider.com News Articles

Vistra Energy (VST) PT Lowered to $194 at BofA Securities

Tue, 27 Oct 2026 04:05:38 -0400

BofA Securities analyst Ross Fowler lowered the price target on Vistra Energy (NYSE: VST) to $194.00 (from $196.00) while maintaining a Buy rating.

The analyst comments "We expect VST to report Q3’26 EBITDA of $2,151 mn, which is above prior year’s results of $1,581 mn and near Consensus of $2,173 mn. At retail, we expect to see an uplift of $80 mn driven by higher volumes and pricing, At Texas, we expect to see a benefit of $317 mn driven by higher prices, increased generation, and the reversal of losses from the Martin Lake outage. At East, we expect to see

Vistra Energy (VST) PT Lowered to $194 at BofA Securities

Tue, 27 Oct 2026 04:05:38 -0400

BofA Securities analyst Ross Fowler lowered the price target on Vistra Energy (NYSE: VST) to $194.00 (from $196.00) while maintaining a Buy rating.

HSBC Starts Vistra Energy (VST) at Buy

Thu, 22 Oct 2026 07:47:21 -0400

(Updated - October 22, 2026 7:47 AM EDT)

HSBC analyst Meike Becker initiates coverage on Vistra Energy (NYSE: VST) with a Buy rating and a price target of $190.00.

The analyst comments: “Vistra is part of our generator theme and we rate the stock Buy on 2026-30e EBITDA CAGR of 9% (2030-35e EBITDA CAGR of -2%) and 2026-30e EPS CAGR of 21% (2030-35e EPS CAGR of 3%), above the peer average. We forecast USD14bn of total share buybacks in the next five years. We forecast adjusted TSR of 15% (FY26-32e); our 2030 EBITDA estimates are slightly ahead of consensus.

Vistra is an independent

HSBC Starts Vistra Energy (VST) at Buy

Thu, 22 Oct 2026 07:47:21 -0400

(Updated - October 22, 2026 7:47 AM EDT)

HSBC analyst Meike Becker initiates coverage on Vistra Energy (NYSE: VST) with a Buy rating and a price target of $190.00.

Vistra is an independent

Vistra Energy (VST) PT Lowered to $226 at Morgan Stanley

Wed, 21 Oct 2026 08:23:37 -0400

Morgan Stanley analyst Stephen Byrd lowered the price target on Vistra Energy (NYSE: VST) to $226.00 (from $227.00) while maintaining a Overweight rating.

Vistra Energy (VST) PT Lowered to $176 at Raymond James

Wed, 21 Oct 2026 05:48:23 -0400

Raymond James analyst J.R. Weston lowered the price target on Vistra Energy (NYSE: VST) to $176.00 (from $182.00) while maintaining a Strong Buy rating.

The analyst comments "Vistra (VST) combines a leading competitive generation fleet with an integrated retail platform and increasingly contracted nuclear portfolio. Shares are down ~7% YTD/~23% TTM amid weaker ERCOT forwards, regulatory uncertainty, and slower data center commercialization. Yet major Meta/AWS agreements and the pending Cogentrix acquisition have improved earnings visibility. We believe the selloff discounts considerable commodity weakness while assigning limited value to improving PJM fundamentals and additional contracting opportunities. We reiterate our Strong Buy rating,

Vistra Energy (VST) PT Lowered to $176 at Raymond James

Wed, 21 Oct 2026 05:48:23 -0400

Raymond James analyst J.R. Weston lowered the price target on Vistra Energy (NYSE: VST) to $176.00 (from $182.00) while maintaining a Strong Buy rating.

CIBC Starts Vistra Energy (VST) at Outperformer

Fri, 16 Oct 2026 13:33:08 -0400

CIBC analyst Mark Jarvi initiates coverage on Vistra Energy (NYSE: VST) with a Outperformer rating and a price target of $201.00.

For an analyst ratings summary and ratings history on Vistra Energy click here. For more ratings news on Vistra Energy click here.

Shares of Vistra Energy closed at $154.17 yesterday.

Vistra redeems $1B in Series A preferred stock at $1,000 per share

Thu, 15 Oct 2026 16:10:37 -0400

Vistra Corp. (NYSE: VST) announced the redemption of all one million outstanding shares of its 8.0% Fixed-Rate Reset Cumulative Redeemable Perpetual Preferred Stock, Series A, at $1,000 per share, representing $1.0 billion in aggregate liquidation preference.

The redemption took place on Oct. 15, 2026, in accordance with the governing documents for the Series A Preferred Stock. Vistra had previously declared distributions payable on the same date, meaning no accrued and unpaid dividends remained as of the redemption date.

Following the redemption date, the Series A Preferred Stock ceased to be outstanding, dividends stopped accruing, and all holder rights were terminated except for

Vistra redeems $1B in Series A preferred stock at $1,000 per share

Thu, 15 Oct 2026 16:10:37 -0400

Following the redemption date, the Series A Preferred Stock ceased to be outstanding, dividends stopped accruing, and all holder rights were terminated except for

Vistra Announces Redemption of All Outstanding Series A Preferred Stock

Thu, 15 Oct 2026 16:10:00 -0400

IRVING, Texas, Oct. 15, 2026 /PRNewswire/ -- Vistra Corp. (NYSE: VST) today announced its redemption of all outstanding shares of its 8.0% Fixed-Rate Reset Cumulative Redeemable Perpetual Preferred Stock, Series A, $0.01 par value per share (the "Series A Preferred Stock") in accordance with the terms and conditions set forth in the governing documents for the Series A Preferred Stock.

Vistra Announces Redemption of All Outstanding Series A Preferred Stock

Thu, 15 Oct 2026 16:10:00 -0400

Form 4 Vistra Corp. For: Oct 07 Filed by: Moldovan Kristopher E.

Thu, 08 Oct 2026 19:45:00 -0400

si-local-file:///var/storage/secattach/20261008/27167981.html

Insu Therapeutics gets U.S. patent allowance for buccal drug delivery

Thu, 08 Oct 2026 07:30:56 -0400

Victory Square Technologies Inc. (CSE: VST) (OTCQX: VSQTF) announced that its portfolio company, Insu Therapeutics Inc., has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering buccal peptide-delivery technology.

The allowance relates to U.S. Patent Application No. 18/513,373, titled "Mucoadhesive Pharmaceutical Dosage Form for Unidirectional Release of Peptide Therapeutic Particles." The application covers a layered dosage form designed to adhere to the inner cheek and direct the release of a peptide medicine toward underlying tissue. Formal patent issuance remains subject to payment of the required issue fee and completion of remaining formalities.

The allowance

Insu Therapeutics gets U.S. patent allowance for buccal drug delivery

Thu, 08 Oct 2026 07:30:56 -0400

The allowance

Insu Therapeutics receives U.S. patent allowance for buccal insulin delivery

Thu, 08 Oct 2026 07:30:37 -0400

Insu Therapeutics Inc., a Vancouver-based biotechnology company in which Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) holds a strategic investment, has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering its buccal peptide-delivery technology.

The allowance relates to U.S. Patent Application No. 18/513,373, titled "Mucoadhesive Pharmaceutical Dosage Form for Unidirectional Release of Peptide Therapeutic Particles." The allowed claims cover the platform's mucoadhesive, layered dosage-form architecture and unidirectional release mechanism for insulin and GLP-1 therapeutics. The published application identifies semaglutide, liraglutide, dulaglutide and exenatide, alongside multiple insulin analogues.

The patent allowance supports Insu's two investigational

Insu Therapeutics receives U.S. patent allowance for buccal insulin delivery

Thu, 08 Oct 2026 07:30:37 -0400

The allowance relates to U.S. Patent Application No. 18/513,373, titled "Mucoadhesive Pharmaceutical Dosage Form for Unidirectional Release of Peptide Therapeutic Particles." The allowed claims cover the platform's mucoadhesive, layered dosage-form architecture and unidirectional release mechanism for insulin and GLP-1 therapeutics. The published application identifies semaglutide, liraglutide, dulaglutide and exenatide, alongside multiple insulin analogues.

The patent allowance supports Insu's two investigational

Insu Therapeutics receives U.S. patent allowance for buccal insulin delivery

Thu, 08 Oct 2026 07:30:37 -0400

The allowance relates to U.S. Patent Application No. 18/513,373, titled "Mucoadhesive Pharmaceutical Dosage Form for Unidirectional Release of Peptide Therapeutic Particles." The allowed claims cover the platform's mucoadhesive, layered dosage-form architecture and unidirectional release mechanism for insulin and GLP-1 therapeutics. The published application identifies semaglutide, liraglutide, dulaglutide and exenatide, alongside multiple insulin analogues.

The patent allowance supports Insu's two investigational

Insu Therapeutics receives U.S. patent allowance for buccal insulin delivery

Thu, 08 Oct 2026 07:30:37 -0400

The allowance relates to U.S. Patent Application No. 18/513,373, titled "Mucoadhesive Pharmaceutical Dosage Form for Unidirectional Release of Peptide Therapeutic Particles." The allowed claims cover the platform's mucoadhesive, layered dosage-form architecture and unidirectional release mechanism for insulin and GLP-1 therapeutics. The published application identifies semaglutide, liraglutide, dulaglutide and exenatide, alongside multiple insulin analogues.

The patent allowance supports Insu's two investigational

Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform